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Venous outcomes consensus statement: Special
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In response to the need for a disease severity measurement, the American Venous Forum committee on outcomes
assessment developed the Venous Severity Scoring system in 2000. There are three components of this scoring system, the
Venous Disability Score, the Venous Segmental Disease Score, and the Venous Clinical Severity Score (VCSS). The VCSS
was developed from elements of the CEAP classification (clinical grade, etiology, anatomy, pathophysiology), which is the
worldwide standard for describing the clinical features of chronic venous disease. However, as a descriptive instrument,
the CEAP classification responds poorly to change. The VCSS was subsequently developed as an evaluative instrument
that would be responsive to changes in disease severity over time and in response to treatment.
Based on initial experiences with the VCSS, an international ad hoc working group of the American Venous Forum was
charged with updating the instrument. This revision of the VCSS is focused on clarifying ambiguities, updating terminology,
and simplifying application. The specific language of proven quality-of-life instruments was used to better address the issues of
patients at the lower end of the venous disease spectrum. Periodic review and revision are necessary for generating more
universal applicability and for comparing treatment outcomes in a meaningful way. (J Vasc Surg 2010;52:1387-96.)As awareness of the morbidity and socioeconomic con-
sequences of chronic venous disease has increased, so has
the technology available for treatment. A critical need now
exists for outcomes assessment instruments that reflect the
morbidity associated with chronic venous disease and the
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doi:10.1016/j.jvs.2010.06.161response to treatment. Several instruments have been de-
veloped that serve to describe the severity of disease or
to measure clinical outcomes. Disease-specific patient-
reported quality-of-life tools are popular in venous disease
reporting and have high sensitivity.1 Tools relying on phy-
sician observation classify venous disease and evaluate clin-
ically relevant changes over time.2 Many of these outcomes
tools have been validated,3-5 and each has strengths and
weaknesses. The Venous Clinical Severity Score (VCSS)
was designed not to replace the CEAP classification but to
supplement it and provide a method for serial assess-
ment.6,7 It was also designed to give additional weight to
more severe manifestations of chronic venous disease
(CEAP clinical class 4 and class 6).6 It has been shown to
withstand differences in intraobserver and interobserver
reproducibility and to be responsive to change.3
The VCSS has been used and evaluated in multiple stud-
ies,7-13 with varied results. Despite widespread use of the
CEAPclinical class and the large volumeof venous procedures
being performed, use of theVCSS has been limited. Although
the usefulness of the VCSS has been clearly demonstrated,
several areas of deficiency have also been noted.9,10,12 Ambi-
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shortcoming of the instrument.9 Other investigators have
suggested that the VCSS is more appropriate for use in severe
chronic venous disease.13
In response to these initial experiences with the VCSS
and under the auspices of the American Venous Forum, an
ad hoc outcomes working group of international, interdis-
ciplinary experts was assembled to evaluate and revise the
current VCSS. The intent of this revision (Table I) includes
continuing to promote use of the instrument, while not
undermining current databases and ongoing trials. An ex-
cellent model of an accepted refinement is found in “Revi-
sion of the CEAP Classification for Chronic Venous Disor-
ders: Consensus Statement.”14 The specific language of
proven quality-of-life instruments was used to better ad-
dress the issues of patients at the less severe disease end of
the venous disease spectrum. The objective of this revision
Table I. Revised Venous Clinical Severity Score
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stockingsis to improve the VCSS, while acknowledging its limita-tions and preserving its strengths (Table II). Future studies
are in progress to validate the reliability, reproducibility,
and responsiveness of the revised VCSS.
METHODS
At the 20th Annual Meeting of the American Venous
Forum in 2008, an outcomes ad hoc working group was
created to review and revise the original VCSS (Table III).
This group evaluated available patient-reported and clinical
outcomes instruments, examined studies regarding use of
the VCSS, and considered recommendations from the as-
sembled experts. In addition to several meetings, corre-
spondence was conducted by e-mail. Published studies
using the VCSS were reviewed and considered for this
revision. Based on these interactions, the clinical descrip-
tors were altered to clarify the language and use universally
accepted terms, while retaining the basic construct of the
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On a separate form, the clinician will be asked to:
“For each leg, please check 1 box for each item (symptom and sign) that is listed below.”
Pain or other discomfort (ie, aching, heaviness, fatigue, soreness, burning)
The clinician describes the four categories of leg pain or discomfort that are outlined below to the patient and asks the patient to
choose, separately for each leg, the category that best describes the pain or discomfort the patient experiences.
None  0: None
Mild  1: Occasional pain or discomfort that does not restrict regular daily activities
Moderate  2: Daily pain or discomfort that interferes with, but does not prevent, regular daily activities
Severe  3: Daily pain or discomfort that limits most regular daily activities
Varicose Veins
The clinician examines the patient’s legs and, separately for each leg, chooses the category that best describes the patient’s superficial
veins. The standing position is used for varicose vein assessment. Veins must be 3 mm in diameter to qualify as “varicose veins.”
None  0: None
Mild  1: Few, scattered, varicosities that are confined to branch veins or clusters. Includes “corona
phlebectatica” (ankle flare), defined as 5 blue telangiectases at the inner or
sometimes the outer edge of the foot
Moderate  2: Multiple varicosities that are confined to the calf or the thigh
Severe  3: Multiple varicosities that involve both the calf and the thigh
Venous Edema
The clinician examines the patient’s legs and, separately for each leg, chooses the category that best describes the patient’s pattern of leg
edema. The clinician’s examination may be supplemented by asking the patient about the extent of leg edema that is experienced.
None  0: None
Mild  1: Edema that is limited to the foot and ankle
Moderate  2: Edema that extends above the ankle but below the knee
Severe  3: Edema that extends to the knee or above
Skin Pigmentation
The clinician examines the patient’s legs and, separately for each leg, chooses the category that best describes the patient’s skin
pigmentation. Pigmentation refers to color changes of venous origin and not secondary to other chronic diseases.
None  0: None, or focal pigmentation that is confined to the skin over varicose veins
Mild  1: Pigmentation that is limited to the perimalleolar area
Moderate  2: Diffuse pigmentation that involves the lower third of the calf
Severe  3: Diffuse pigmentation that involves more than the lower third of the calf
Inflammation
The clinician examines the patient’s legs and, separately for each leg, chooses the category that best describes the patient’s skin
inflammation. Inflammation refers to erythema, cellulitis, venous eczema, or dermatitis, rather than just recent pigmentation.
None  0: None
Mild  1: Inflammation that is limited to the perimalleolar area
Moderate  2: Inflammation that involves the lower third of the calf
Severe  3: Inflammation that involves more than the lower third of the calf
Induration
The clinician examines the patient’s legs and, separately for each leg, chooses the category that best describes the patient’s skin
induration. Induration refers to skin and subcutaneous changes such as chronic edema with fibrosis, hypodermitis, white atrophy, and
lipodermatosclerosis.
None  0: None
Mild  1: Induration that is limited to the perimalleolar area
Moderate  2: Induration that involves the lower third of the calf
Severe  3: Induration that involves more than the lower third of the calf
Active Ulcer Number
The clinician examines the patient’s legs and, separately for each leg, chooses the category that best describes the number of active
ulcers.
None  0: None
Mild  1: 1 ulcer
Moderate  2: 2 ulcers
Severe  3: 3 ulcers
Active Ulcer Duration
If there is at least 1 active ulcer, the clinician describes the 4 categories of ulcer duration that are outlined below to the patient and asks
the patient to choose, separately for each leg, the category that best describes the duration of the longest unhealed ulcer.
None  0: No active ulcers
Mild  1: Ulceration present for 3 mo
Moderate  2: Ulceration present for 3-12 mo
Severe  3: Ulceration present for 12 mo
ockin
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clinical descriptors. Each limb is considered and scored
separately.
EXPLANATION OF REVISIONS TO THE
CLINICAL DESCRIPTORS IN THE CURRENT
VERSION
The first descriptor, pain, was amended to include
frequently encountered patient symptoms including ach-
ing, heaviness, fatigue, soreness, and burning. These terms
are pertinent in establishing pain as venous in origin,15 and
usually change in response to treatment, as has been demon-
strated by disease-specific quality-of-life measures.1,4,5,16-18
Pain with exercise, as more commonly experienced with
iliofemoral obstruction (ie, venous claudication19) may be
scored with this component. The pain component was also
modified to assess its limiting effect on regular daily activi-
ties. Pain of nonvenous origin (such as arthritic or at the site
of a treatment) is not to be included in this category.
Within the second descriptor, varicose veins, the vein
size criterion was modified to “at least 3-mm diameter” to
remain consistent with the revised CEAP classification.14 In
this definition, “varicose veins” involve any subcutaneous
saphenous veins, saphenous tributaries, or nonsaphenous
superficial leg veins. The standing position for varicose vein
assessment has been clarified in the instructions for use
(Table II). Therefore, an overall change in the standing
position size of previously engorged or enlarged veins may
affect the score of this section if those veins shrink to less
than 3 mm in diameter. Varicosities that are confined to
either the calf or thigh are distinguished from varicosities
that are present in both the calf and thigh. Great saphenous
varicose vein distributions are not differentiated from small
saphenous vein distributions in this revised version. Telan-
giectasias and reticular veins are still not included and
remain without a score. Corona phlebectatica (ankle flare)
is defined as more than five blue telangiectasias on the inner
or outer edge of the foot. Corona phlebectatica is associ-
ated with chronic venous insufficiency (CVI) and perfora-
tor reflux 20 but is not truly “skin pigmentation,” which is
defined by the revised CEAP classification as “brownish
Table II. Continued.
Active Ulcer Size
If there is at least 1 active ulcer, the clinician examines the patient
describes the size of the largest active ulcer.
None  0: No active ulcer
Mild  1: Ulcer 2 cm in dia
Moderate  2: Ulcer 2-6 cm in dia
Severe  3: Ulcer 6 cm in dia
Use of Compression Therapy
Choose the level of compliance with medical compression therapy
None  0: Not used
Mild  1: Intermittent use
Moderate  2: Wears stockings mo
Severe  3: Full compliance: stdarkening of skin, resulting from extravasated blood.”14Therefore, corona phlebectatica was added to the mild cat-
egory and assigned a score of 1 (Fig 1).
The third descriptor, venous edema, was amended to
reflect the anatomic distribution and extent. Edema of
presumed venous origin is defined in the revised CEAP
classification as a “perceptible increase in volume of fluid in
skin and subcutaneous tissue, characteristically indented
with pressure.”14 The revised VCSS edema attribute is
scored by extent: (1) limited to the foot and ankle, (2)
extends above the ankle but below the knee, or (3) extends
to the knee or above. Considering that patients have differ-
ing daily routines, the clinician’s examination should be
supplemented by asking the patient about the nature and
extent of leg edema experienced.
Guideline criteria are now provided for the fourth
attribute, skin pigmentation, with regard to both anatomic
distribution and extent. This is also reflected in the inflam-
mation and induration categories. The criteria include skin
pigmentation that is (1) limited to the perimalleolar area,
(2) involves the lower third of the calf, or (3) extends
beyond the lower third of the calf. Skin pigmentation refers
only to color changes of venous origin and not those related
to other chronic diseases such as vasculitis purpura. Focal
pigmentation that is confined to the skin over a varicose
vein is not considered to signify the same severity of venous
disease as more diffuse pigmentation and is given a score of
Fig 1. Corona phlebectatica.
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tomy, or sclerotherapy should not be included in the assess-
ment of skin pigmentation. Different levels of pigmenta-
tion are illustrated in Fig 2.
The inflammation fifth descriptor was expanded to
focus on more than just recent skin pigmentation
changes or underlying infection. Inflammation here re-
fers to the acute aspects of venous disease, those likely to
respond to treatment, which may occur at the same time
as other more chronic changes of skin pigmentation,
induration, or ulceration. The terms erythema, cellulitis,
venous eczema, and dermatitis were incorporated here.
Also, the descriptors now provide for anatomic distribu-
tion and extent, similar to the skin pigmentation and
induration categories (Fig 3).
Induration, the sixth descriptor, was modified to
reflect more severe venous disease. Chronic edema with
fibrosis, hypodermitis, white atrophy, and lipodermatoscle-
rosis were terms added in part to promote more universal
use. It is recognized that this category, similar to skin
pigmentation, is usually much slower to respond to
treatment, if at all. For simplicity, the distribution lan-
guage is the same as that for skin pigmentation and
inflammation (Fig 4).
In the active ulcer categories, descriptor 7 (ulcer num-
ber) remains unchanged. Descriptors 8 and 9 were refined
Table III. Original Venous Clinical Severity Score
Attribute Absent  0 Mild  1
Pain None Occasional, not rest
activity or requiri
analgesics
Varicose veinsa None Few, scattered: bran
VVs
Venous edemab None Evening ankle edem
Skin pigmentationc None or focal, low
intensity (tan)
Diffuse, but limited
area and old (bro
Inflammation None Mild cellulitis, limit
marginal area aro
ulcer
Induration None Focal, circummalleo
(5 cm)
No. of active ulcers 0 1
Active ulceration,
duration
None 3 mo
Active ulcer, sized None 2-cm diameter
Compressive
therapye
Not used or not
compliant
Intermittent use of
stockings
a“Varicose” veins must be 4-mm diameter to qualify so that differentiatio
bPresumes venous origin by characteristics (eg, brawny [not pitting or spong
evidence of venous etiology (ie, varicose veins, history of DVT). Edema mu
qualify.
cFocal pigmentation over varicose veins does not qualify.
dLargest dimension/diameter of largest ulcer.
eSliding scale to adjust for background differences in use of compression thin regard to ulcer size and ulcer duration. The largest activeulcers should be scored in the size category. The longest
active ulcer should be scored in the duration category.
Healed ulcers or a history of ulcers should be included in
earlier clinical descriptors. A large ulcer that becomes sep-
arated by a healing bridge of tissue should still be consid-
ered a single ulcer and is given a score of 1 (Fig 5).
Inclusion of the final 10th clinical descriptor, use of
compression therapy, has perhaps been themost controver-
sial element of the original VCSS. It is recognized that use
of compression therapy is not itself a measure of venous
severity. However, use of compression therapy is a measure
of compliance with conservative measures and generally
will lead to diminished symptoms or signs (ie, pain, venous
edema, and active ulcer) and thus a lower VCSS. Addition-
ally, use of compression therapy has no effect on the change
in severity score if the background of compression use does
not change during the therapy. Although removing this
attribute from the VCSS was seriously debated, doing this
would constitute a major revision to the VCSS, upset
ongoing data collections using the original VCSS, and is
not clearly supported by available evidence. Therefore, the
compression therapy descriptor was changed only to elim-
inate the additional variable of leg elevation. The descrip-
tion of the frequency with which a compression garment is
worn remains unchanged in this revised version of the
Moderate  2 Severe  3
g Daily, moderate activity
limitation, occasional
analgesics
Daily, severe limiting
activities or requiring
regular use of analgesics
Multiple: GS varicose veins
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Reporting of clinical outcomes in a standard fashion is
expected by physician societies, hospitals, third-party pay-
ers, and government agencies. Such standardized reporting
practices are required to compare devices and other thera-
peutic methods intended to improve clinical outcomes.
Despite the tremendous increases in venous technologies
and procedural volumes over the past decade, clinical out-
come reporting continues to be lagging.2,21 Surrogate
outcomes, such as vein occlusion rates, stent patency, and
changes in venous hemodynamics do not necessarily relate
to a clinical change.
As physicians, we have an obligation to demonstrate
that our interventions are based on best available evidence
and use outcomes that are of importance to the patient and
to society, rather than surrogate markers of unclear or
doubtful significance.
Although the VCSS is derived directly from the
CEAP clinical class, it was intended to supplement, not
replace, the CEAP classification by providing a method
for serial assessment over time and in response to an
intervention.6,7,11,12 The VCSS is evaluative and longi-
tudinal, while the CEAP classification is descriptive and
Fig 2. Skin pigmentation. A, Perimalleolar. B, Lower third calf.
C, Above lower third calf.relatively static, especially in classes 4 through 6.2,3,6,7Although useful, the original VCSS remains imperfect.
Perrin et al13 reviewed important deficiencies in the
VCSS. In their opinion, the usefulness of VCSS seemed
lower for C1-C3 patients compared with C4-C6 pa-
tients, and VCSS was not precise enough with regard to
skin changes such as dermatitis or hypodermic inflamma-
tion. However, Perrin and colleagues also noted that
community-practicing French angiologists found the
VCSS easy to use. The VCSS is generated by the clinician
during the course of routine patient examination and can
be followed readily. It has been argued that the VCSS
fails to include cosmetic concerns, but inclusion of cos-
metic issues is considered inappropriate in measuring the
clinical severity of chronic venous disease in venous
disease-specific quality-of-life studies.4,22 Use of the cur-
rent VCSS has proven valuable among patients with
milder CEAP class 2 and class 3 disease in several stud-
ies.12,23,24 Nevertheless, significant concerns remain re-
garding restrictive, misleading, confusing, and/or in-
complete clinical descriptors, which primarily led to this
revision.
Numerous venous disease-specific quality-of-life in-
struments have proven useful in large cohorts of pa-
tients.1,11,16,22,25 They have been found to be valid, sensi-
tive, reliable, relevant, and responsive.1,16,22 They represent
patient-derived constructs and have been designed to bridge
objective and subjective evaluations. Multiple stud-
ies4,8,9,10,11 have demonstrated the relationship between
patient-derived and physician-evaluated tools. For patients
with minimal symptoms, both patient-perceived and phy-
sician-evaluated tools are less valuable.4,7,22 Although use-
ful for research, quality-of-life instruments have been found
by many clinicians to be time-consuming to complete and
cumbersome to follow in daily practice.5,17 There may be
language or cultural barriers to proper application of some
of these instruments.18,26 In addition, the clinician may
find difficulty in choosing from themany that are available.2
Nevertheless, quality-of-life tools and the VCSS provide
complementary information. If an instrument like the
VCSS could be infused with the language that patients use
in describing their venous symptoms and if the most valu-
able elements of quality of life could be combined with a
practical clinical outcomes tool, such an instrument could
have wide applicability. For example, the score by Villalta
et al27 was designed for patients with post-
thrombotic syndrome. Although this score has proven useful
in this particular group of patients, it is not intended for
broader use, in patients with CVD from other causes. The
VCSS can be used to assess the broader spectrum of
chronic venous disease as well as to compare patients
with postthrombotic syndrome, those subjected to dif-
ferent treatment modalities of saphenous venous abla-
tion, stenting for venous obstruction, pharmacome-
chanical thrombolysis, etc.
Reporting the CEAP clinical class in combination with
the revised VCSS can add substantial clinical information.
For example, CEAP clinical class 6 disease can only improve
to class 5; class 4 disease may remain unchanged, despite
Fig 3. Inflammation. A, Cellulitis. B
Fig 4. Induration. A, White atrophy. B, Lipodermatosclerosis.
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tients with class 2 and class 3 level disease varies widely.
Linking the VCSS to the clinical CEAP conveys a large
amount of complementary information that enhances com-
munication. Figs 6 through 9 illustrate a more vivid and
dynamic clinical picture.
There is considerable overlap in the three active ulcer
categories. Therefore, a dramatic VCSS score reduction
usually occurs when an ulcer heals. Although the original
VCSS was designed to be more heavily weighted toward
the higher CEAP classes, this overlap has been thought
to be excessive and will likely be amended in future
revisions. Progression of CVD with clinical deterioration
over time can be documented by the VCSS. In addition,
a number of patients will develop recurrent disease after
treatment.15,28 The VCSS has a role in assessing these
patients as well.
The current revision of the VCSS is designed primar-
ily to clarify the clinical descriptors and thus make the
instrument more precise. The issues of greatest concern
with the current VCSS were addressed, and the lessons
learned from the quality-of-life instruments were incor-
, Dermatitis. C, Venous eczema.
Fig 5. Number of active ulcers (remains 1 ulcer in healing
phase).porated. A potential shortcoming of this revision is that
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VCSS and continues to represent a consensus of expert
opinion. Nevertheless, making minor revisions to the
clinical descriptors was considered an important first step
toward a more thorough evaluation of the instrument. In
addition, observer-expectancy effect is a possibility with
any physician-generated outcomes assessment tool.
Studies evaluating the validity, reliability, and respon-
siveness of the revised VCSS are in progress and may well
lead to further revisions.
CONCLUSION
With greater understanding of CVD, the ability to
follow clinically relevant outcomes should increase. Fu-
Fig 6. The “visual language” of VCSS. Consistency in
of venous disease to emerge. A, Before treatment basic
Pain  1, VV  2, Edema  2, Pigmentation  0
duration  0, Compression  2. Total VCSS  7. B,
3. Pain  0, VV  1, Edema  0, Pigmentation 
duration  0, Compression  2. Total VCSS  3.
Clinical descriptor Absent (0) Mild (1)
Pain None Occasional
Varicose veins None Few
Venous edema None Foot and ankle
Skin pigmentation None Limited perimalle
Inflammation None Limited perimalle
Induration None Limited perimalle
No. active ulcers None 1
Ulcer duration None 3 mo
Active ulcer size None 2 cm
Compression therapy None Intermittentture changes are likely to be needed to maintain thedynamic nature of this instrument. The VCSS is the
progeny of the CEAP clinical class and has a precedent in
the revised CEAP classification. It has been shown to be
practical and easy to use. This document updates termi-
nology, simplifies application, and eliminates identified
ambiguities of the original VCSS to produce an instru-
ment that can be accepted as valid, reliable, and useful by
the international venous community. The revised VCSS
coupled to clinical CEAP provides a standard clinical
language to report and compare differing approaches to
CVD management.
The authors thank Thomas Wakefield, MD, and
Carolyn Munschauer, BA for their great help with this
ician scoring and reporting allows a common language
cal CEAP 3-VCSS 7. Revised VCSS scoring as follows:
ammation  0, Induration  0, Active ulcers, size,
treatment, scoring changes to clinical CEAP 2-VCSS
flammation  0, Induration  0, Active ulcers, size,
Moderate (2) Severe (3)
Daily not limiting Daily limiting
Calf or thigh Calf and thigh
Below knee Knee and above
Diffuse lower 1/3 calf Wider above lower 1/3 calf
Diffuse lower 1/3 calf Wider above lower 1/3 calf
Diffuse lower 1/3 calf Wider above lower 1/3 calf
2 3 or more
3-12 mo 1 y
2-6 cm 6 cm
Most days Fully complyphys
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Compression  2. Total VCSS  9.
duration  0, Compression  2. Total VCSS  11.
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Fig 9. The broadened language of uniting CEAP with VCSS in
CVD. More information is relayed in stating C6-V25 changes to
C6-V21 and at last C5-V7. A, Pre – Pain  3, VV  3, Edema 
2, Pigmentation  2, Inflammation  3, Induration  2, Active
ulcers 1, size 3, duration 3, Compression 3.Total VCSS
25.B,1week post – Pain2,VV 2, Edema 1, Pigmentation
2, Inflammation 2, Induration 2, Active ulcers 1, size 3,
duration 3, Compression 3. Total VCSS 21. C, 2 months
post – Pain  0, VV  1, Edema  0, Pigmentation  2,
Inflammation  0, Induration  2, Active ulcers  0, size  0,
duration  0, Compression  2. Total VCSS  7.Fig 7. A,Before treatment clinical C4 -VCSS16. Pain2,VV1,
Edema 2, Pigmentation 3, Inflammation 3, Induration 3,
Active ulcers, size, duration  0, Compression  2. Total VCSS 
16. B, Four months after treatment, patient remains clinical C4, but
C4-V9. Pain  0, VV  1, Edema  1, Pigmentation  3, Inflam-
mation  0, Induration  2, Active ulcers, size, duration  0,Fig 8. A, Prior to treatment, clinical C6-V18. Pain 3, VV 3,
Edema  2, Pigmentation  3, Inflammation  1, Induration 
2, Active ulcers  1, size  1, duration  1, Compression  1.
Total VCSS  18. B, One month after treatment, clinical C5-
V11. Pain  1, VV  2, Edema  1, Pigmentation  3,
Inflammation  0, Induration  2, Active ulcers  0, size  0,Obtained funding: Not applicable
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